Perioperative Nivolumab Tops Chemo for Survival in Resectable Lung Cancer
FRIDAY, May 17, 2024-- For patients with resectable non-small cell lung cancer (NSCLC), perioperative treatment with nivolumab results in significantly longer event-free survival, according to a study published in the May 16/23 issue of the New...